Skip to main content
. 2016 Jun 8;9:3423–3432. doi: 10.2147/OTT.S100706

Figure 2.

Figure 2

Forest plot showing the pooled HR from the fixed-effects model for PFS in axitinib vs sorafenib treatments in mRCC patients.

Abbreviations: CI, confidence interval; HR, hazards ratio; mRCC, metastatic renal cell carcinoma; PFS, progression-free survival.